Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer (NSCLC): Pooled analysis of two randomized trials.

@article{Ardizzoni2011PemetrexedVP,
  title={Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer (NSCLC): Pooled analysis of two randomized trials.},
  author={Andrea Ardizzoni and Luca Boni and M Tiseo and Andrew Vincent and R Walter Passalacqua and A Camerini and Roberto Labianca and Giovenzio Genestreti and Francesca Zanelli and Libero Ciuffreda and Francesco di Costanzo and Filippo De Marinis and Lucio Crin{\`o} and Antonio Santo and Antonio Pazzola and Fausto Barbieri and Nicoletta Zilembo and Ida Colantonio and Carmelo Tibaldi and Egbert Frederik Smit},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={7555}
}
7555 Background: To evaluate the benefit of adding carboplatin (C) to pemetrexed (P) chemotherapy (CT) in 2nd-line therapy of advanced NSCLC, by pooling results of 2 identical randomized phase II trials (GOIRC 02.2006 and NVALT-7) carried out in Italy and The Netherlands, respectively. METHODS Eligibility criteria in both trials included: diagnosis of advanced NSCLC, disease progression after 1st-platinum-based CT and PS 0-2. Patients (pts) were randomized to P 500 mg/m2 alone or combined… CONTINUE READING
BETA